iSBTc 23rd Annual Meeting
Annual Meeting Main Page | Program Purpose | Faculty | CME Information | Award Winners
Supporters | Presentation Slides & Schedule
| Photos | Download Abstracts
Supporters | Presentation Slides & Schedule
| Photos | Download AbstractsOctober 31 - November 2, 2008
Westin Gaslamp Quarter Hotel
San Diego, CA
Presentation Slides & Schedule
Slides for select presentations below have been provided by the corresponding speaker for your convenience.
Please click the next to the speaker's name to log in to view the presentations.
| Wednesday, October 29 | |||
| 11:00 am - 7:00 pm | Registration Open | ||
| Thursday, October 30 | |||
| 6:30 am - 6:00 pm | Registration Open | ||
| Friday, October 31 | |||
| 6:30 am - 5:00 pm | Registration Open | ||
| 10:00 am - 4:00 pm | Exhibit Hall Open | ||
| 10:00 am - 7:30 pm | Poster Hall Open | ||
| 7:50 am - 8:00 am | President's Welcome Jon M. Wigginton, MD - Merck & Co., Inc. |
||
| 8:00 am - 8:45 am | Richard V. Smalley, MD Memorial Lectureship Different Tumor Antigens in the Immunotherapy of Cancer: Are we Selecting the Right Target? Giorgio Parmiani, MD - San Raffaele Foundation
|
||
| 8:45 am - 11:30 am | Plenary Session: Enhancing Cancer Vaccines
|
||
| 8:45 am - 9:15 am | Enhancing Cancer Vaccines Through Heterologous Prime Boost Strategies that Include VRP and that Induce Lifelong Protection from Prostate Cancer and Therapy of Cervical Cancer in Mice and Robust Cell-Mediated Immunity in Rhesus Macaques W. Martin Kast, PhD - University of Southern California |
||
| 9:15 am - 9:30 am | Interleukin-15 and its Receptor Enhance Antitumor Activity Following a Genetically-Modified Dendritic Cell Vaccine Jason C. Steel, PhD - National Cancer Institute, Metabolism Branch, NIH |
||
| 9:30 am - 9:45 am | T Cell Receptor-Dependent and Independent Pathways Control PD-1 Expression on CD8+ T cells Generated upon Intra Lymph Node Immunization Adrian Bot, MD, PhD - MannKind Corporation |
||
| 9:45 am - 10:00 am | Cellular Immunotherapy and Immune Regulation in Ovarian Cancer Martin J. Cannon, PhD - University of Arkansas for Medical Sciences |
||
| 10:00 am - 10:15 am | Intra-Lymphatic Continuous Infusion of Dendritic Cells in Patients with Advanced Melanoma: Early Indication of Clinical Efficacy Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute |
||
| 10:45 am - 11:00 am | Clinical Response to the MAGE-A3 Immunotherapeutic in Metastatic Melanoma Patients is Associated with a Specific Gene Expression Profile Present at the Tumor Site Jamila Louahed, PhD - GlaxoSmithKline Biologicals SA |
||
| 11:00 am - 11:30 am | Balancing Tumor Immunity and Inflammation Glenn Dranoff, MD - Dana-Farber Cancer Institute |
||
| 11:30 am - 1:00 pm | Lunch with Poster Viewing | ||
| 1:00 pm - 3:00 pm | Plenary Session: Adoptive Transfer
|
||
| 1:00 pm - 1:30 pm | Three Ways to Enhance the Destructive Power of Tumor-Specific T Cells Nicholas P. Restifo, MD - National Cancer Institute |
||
| 1:30 pm - 2:00 pm | Engineering GVL by T-Cell Genetic Modification Michael C.V. Jensen, MD - City of Hope / Beckman Research Institute |
||
| 2:00 pm - 2:15 pm | Targeted Elimination of Brain Tumor Stem Cells with T Cell Therapies Christine Brown, PhD - City of Hope National Medical Center |
||
| 2:15 pm - 2:30 pm | Intralesional Placement of Lymphokine-Activated Killer Cells After Resection of Primary Glioblastoma Robert O. Dillman, MD, FACP - Hoag Cancer Center |
||
| 2:30 pm - 2:45 pm | Provision of CD4+ T Cell Help Prevents Tolerization of Tumor-Specific CTLs and
Enhances Tumor Immunity in a Murine Model of Prostate Cancer Kimberly A. Shafer-Weaver, PhD - SAIC/NCI-Frederick |
||
| 2:45 pm - 3:00 pm | Rapid Expansion of Melanoma TIL in Adoptive Cell Therapy Leads to Loss of CD28 and
Reduced Proliferative Potential in the MART-1-Specific T Cell Population Yufeng Li - MD Anderson Cancer Center |
||
| 3:15 pm - 4:45 pm | Concurrent Session I: TH-17, Cytokines and T Cell Subsets
|
||
| 3:15 pm - 3:40 pm | IL-23 Promotes Tumor Associated Inflammation and Subverts Immune Surveillance Martin Oft, MD - Schering-Plough Biopharma (formerly DNAX) |
||
| 3:40 pm - 4:05 pm | Potent Anti-Tumor Immunity and Both TH-1 and TH-17 Promotion Associated with
IL-23 Administration Hideaki Tahara, MD, PhD - University of Tokyo |
||
| 4:05 pm - 4:30 pm | TH-17 Cells in Ovarian Cancer Patients Ilona Kryczek, PhD - University of Michigan |
||
| 4:30 pm - 4:45 pm | CD40 Dependent Induction of TH-17 Effector Cells from T Regulatory Cells Using the
Immune Modulator B7-DC XAb Suresh Radhakrishnan, PhD - Mayo Clinic, College of Medicine This abstract was fully retracted May 28, 2010 upon request of the Principal Investigator. |
||
| 3:15 pm - 4:45 pm | Concurrent Session II: Endpoints, Response Criteria for Clinical Trial Design
|
||
| 3:15 pm - 3:40 pm | Immunotherapies in Combination with Other Therapeutic Modalties: New Paradigms for Clinical Trial Design Jeffrey Schlom, PhD - National Cancer Institute, NIH |
||
| 3:40 pm - 3:55 pm | Overall Survival and New Patterns of Response in Patients with Advanced Melanoma Treated with Ipilimumab Steven J. O'Day, MD - The Angeles Clinic and Research Institute |
||
| 3:55 pm - 4:15 pm | Endpoints for Biologic Therapeutics in Oncology Peter Bross, MD - FDA - Office of Cellular, Tissue, and Gene Therapies |
||
| 4:15 pm - 4:45 pm | Panel Discussion | ||
| 5:00 pm - 5:30 pm | iSBTc Membership Business Meeting (iSBTc Members Only) | ||
| 5:30 pm - 7:30 pm | Reception with Poster Viewing | ||
| Saturday, November 1 | |||
| 7:00 am - 6:00 pm | Registration Open | ||
| 7:00 am - 8:00 am | Continental Breakfast | ||
| 8:00 am - 8:45 am | Keynote Address Cancer Immunoediting: Distinct Roles for Innate and Adaptive Immunity in Cancer Control and Promotion Robert D. Schreiber, PhD - Washington University in St. Louis
|
||
| 8:45 am - 11:30 am | Plenary Session: Tumor Escape / Tumor Microenvironment
|
||
| 8:45 am - 9:15 am | Innate Immune Signals that Mediate Host Awareness of Tumor and Promote Adaptive
Immune Responses Against Tumor Antigens Thomas F. Gajewski, MD, PhD - University of Chicago |
||
| 9:15 am - 9:30 am | Persistent High Grade Cervical Dysplasia Excludes CD8+ T Cells Cornelia Trimble, MD - Johns Hopkins University |
||
| 9:30 am - 10:00 am | Inhibitory B7 Family Members (B7-H1 and B7-H4) in the Tumor Microenvironment Weiping Zou, MD, PhD - University of Michigan |
||
| 10:00 am - 10:15 am | L-Arginine Availability Regulates Cyclin D3 mRNA Stability in Human T Cells by Controlling HuR Expression Paulo C. Rodriguez, PhD - Louisiana State University Health Science Center |
||
| 10:45 am - 11:15 am | Correcting the Anergy of Human Tumor-Infiltrating Lymphocytes? Pierre van der Bruggen, PhD - Ludwig Institute for Cancer Research |
||
| 11:15 am - 11:30 am | Evidence for Selection of a Resistant Tumor Microenvironment Following Successful Clinical Response to a Multi-Peptide + IL-12 Melanoma Vaccine Yuanyuan Zha, PhD - Human Immunologic Monitoring Facility, University of Chicago |
||
| 11:30 am - 1:00 pm | Lunch with Poster Viewing | ||
| 1:00 pm - 2:20 pm | iSBTc Presidential Abstract Session
|
||
| 1:00 pm - 1:20 pm | Increasing Immunostimulatory Ability of Tolerogenic APCs Enhances Anti-Tumor Immunity Stephanie K. Watkins, PhD - National Cancer Institute - Frederick, NIH |
||
| 1:20 pm - 1:40 pm | CCL28 a New Link Between Hypoxia Angiogenesis and Tumor Immune Evasion Andrea Facciabene, PhD - University of Pennsylvania |
||
| 1:40 pm - 2:00 pm | Cytotoxic T Lymphocyte-associated Antigen 4 Blockade Enhances Polyfunctional NY-ESO-1 Specific T Cell Responses in Metastatic Melanoma Patients with Tumor Regression Jianda Yuan, MD, PhD - Memorial Sloan-Kettering Cancer Center |
||
| 2:00 pm - 2:20 pm | Radiofrequency Ablation with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect Against Murine Colon Adenocarcinoma Erik Johnson, MD - University of Wisconsin-Madison |
||
| 2:45 pm - 4:15 pm | Concurrent Session I: Tumor Targeting Monoclonal Antibodies
|
||
| 2:45 pm - 3:15 pm | Antibody and Small Moldular Immune Pharmaceutical Therapies for Patients with Chronic Lymphocytic Leukemia: A Major Step Forward John C. Byrd, MD - The Ohio State University |
||
| 3:15 pm - 3:30 pm | Phase I/II Study of CR011-vcMMAE, an Antibody-Drug Conjugate Targeting GPNMB, for the Treatment of Patients with Advanced Melanoma Patrick Hwu, MD - MD Anderson Cancer Center |
||
| 3:30 pm - 4:00 pm | Optimizing Engagement of the Immune System by Anti-Tumor Antibodies John R. Desjarlais, PhD - Xencor, Inc. |
||
| 4:00 pm - 4:15 pm | Cetuximab Mediated Antibody Dependent Cellular Cytotoxicity by NK Cells Expressing Polymorphic Fc Gamma Receptor (FcyR)IIIa Robert L. Ferris, MD, PhD - University of Pittsburgh Cancer Institute |
||
| 2:45 pm - 4:15 pm | Concurrent Session II: Innate Immunity to Tumors
|
||
| 2:45 pm - 3:15 pm |
Innate Resistance, Inflammation, and Cancer Giorgio Trinchieri, MD - National Cancer Institute |
||
| 3:15 pm - 3:45 pm |
Role of NKG2D in Tumor Surveillance David Raulet, PhD - University of California, Berkeley |
||
| 3:45 pm - 4:00 pm | Innate Immunity Can Contribute to the Shaping of Tumor Immunogenicity in the Absence of Adaptive Immunity Jack D. Bui, MD, PhD - University of California, San Diego |
||
| 4:00 pm - 4:15 pm | Spontaneous CTL-mediated Rejection of GP33-positive Lewis Lung Carcinoma is Dependent on an IFNAR Competent Environment Ulrich Kalinke, PhD - TWINCORE, Centre for Experimental and Clinical Infection Research |
||
| 4:30 pm - 5:00 pm | Update: 2007 Workshop on Future Opportunities for Combination Biological Therapy of Cancer
|
||
| 5:00 pm - 5:15 pm | Award Presentations | ||
| 5:15 pm - 7:00 pm | Presidential Reception with Poster Viewing | ||
| Sunday, November 2 | |||
| 7:00 am - 11:00 am | Registration Open | ||
| 8:00 am - 10:15 am | Plenary Session: Cancer Stem Cells and the Host Response
|
||
| 8:00 am - 8:42 am | Regulation of Breast Cancer Stem Cells by the Microenvironment Max Wicha, MD - University of Michigan |
||
| 8:42 am - 9:24 am | Harnessing the Immune System to Target Stem Cell Genes in Myeloma Madhav Dhodapkar, MD - The Rockefeller University |
||
| 9:24 am - 9:49 am | Characterization of the Immune Profile of Cancer Stem Cells Isolated from Human Glioblastoma Cristina Maccalli, PhD - San Raffaele Foundation Scientific Institute |
||
| 9:49 am - 10:15 am | CD133 as a Potential Target of Anti-cancer Stem Cell Immunotherapy: Identification of a HLA-A*02 Restricted CD133 Epitope John S. Yu, MD - Cedars Sinai Medical Center |
||
| 10:15 am - 10:30 am | Annual Meeting Adjourns | ||
| Sunday Hot Topic Symposium | |||
| 10:30 am - 12:00 pm | Hot Topic Session - "Anti-CTLA-4: Issues in Development and Regulatory Approval" Program to include invited speakers, panel discussion/debate and audience questions. Click here for more information, including a detailed schedule and faculty listing. |
||
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
